Stocks · Healthcare · Biotechnology
Pyxis Oncology, Inc. PYXS
$2.14 -2.28% Close, Oct 2, 2026 · NASDAQ · Market cap $135.6M
Expensive vs sectorHigh risk
Next earnings report: Nov 2, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $11.0M, up 291.4% from a year earlier.
- Operating margin widened to -834.4% from -3776.1% a year earlier.
- The stock is 60% below its highest close of the past year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 5%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 2%
- Gross marginTop 5%
- Operating marginBottom 13%
- Accruals (lower is better)Top 5%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 11%
- Free-cash-flow yieldBottom 8%
- EBITDA / enterprise valueBottom 9%
- Sales / enterprise valueBottom 27%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 25%
- 6-month returnTop 22%
- 1-year return vs S&P 500Bottom 41%
- Distance from 52-week highBottom 15%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 42%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 38%
- Upside to consensus price targetTop 13%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 4%
- Maximum drawdown, 3 yearsBottom 22%
- Beta vs S&P 500 (lower is better)Bottom 28%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Gross margin | 100.0% | 99.8% | ↓ |
| Operating margin | -3776.1% | -834.4% | ↑ |
| FCF margin | -2615.4% | -615.3% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 291.4% | — | Top 5% | |
| Gross margin | 99.8% | 100.0% | ↓ | Top 5% |
| Operating margin | -834.4% | -3776.1% | ↑ | Bottom 13% |
| Net margin | -803.8% | -3414.4% | ↑ | — |
| Free-cash-flow margin | -615.3% | -2615.4% | ↑ | — |
| Return on invested capital | -314.7% | — | Bottom 2% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -37.9%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 107.7%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -391.4 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.58%
- Shareholder yield
- -0.58%
- Share count change, 1 year
- +3.3%
- Share count change, 3-year CAGR
- +18.6%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 13, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 3 of 8
- Average EPS surprise, last 4
- -0.0%
- Average 2-day reaction, last 8
- -2.4%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $7.67
- Target vs current price
- +258.4%
- Analysts with a rating
- 12
- Share rating Buy or Strong Buy
- 83%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 13, 2026 | -14.3% | -5.3% | +6.0% | +2.8% | — |
| May 14, 2026 | -5.7% | -15.6% | -23.7% | -36.3% | +46.2% |
| Mar 23, 2026 | +17.1% | -3.4% | -10.9% | +15.6% | +19.0% |
| Nov 3, 2025 | +2.8% | +7.0% | +9.8% | +23.3% | -56.2% |
| Aug 14, 2025 | +16.7% | +5.6% | +8.4% | +73.8% | +277.6% |
| May 15, 2025 | -20.7% | +3.7% | +7.5% | +14.0% | -2.8% |
| Mar 18, 2025 | -75.8% | -8.6% | +3.4% | -21.1% | +10.3% |
| Nov 12, 2024 | -9.4% | -2.5% | -13.7% | -64.6% | -71.9% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.40 | -$0.35 | -14.3% | — |
| May 14, 2026 | -$0.37 | -$0.35 | -5.7% | — |
| Mar 23, 2026 | -$0.29 | -$0.35 | +17.1% | $11.0M |
| Nov 3, 2025 | -$0.35 | -$0.36 | +2.8% | — |
| Aug 14, 2025 | -$0.30 | -$0.36 | +16.7% | $2.8M |
| May 15, 2025 | -$0.35 | -$0.29 | -20.7% | — |
| Mar 18, 2025 | -$0.58 | -$0.33 | -75.8% | — |
| Nov 12, 2024 | -$0.35 | -$0.32 | -9.4% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 12.19× | — | — | Bottom 27% |
| Free-cash-flow yield | -50.09% | — | — | Bottom 8% |
| Earnings yield | -65.89% | — | — | Bottom 11% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 52
- 50-day average slope (20 days)
- +7.6%
- 200-day average slope (20 days)
- -6.3%
- Distance from 50-day average
- -32.1%
- Distance from 200-day average
- +0.3%
- RSI (14)
- 29.1
- Relative volume
- 1.43×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 126.9%
- Volatility vs own 5-year history
- 78th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.62
- Correlation with S&P 500
- 0.19
- Current drawdown from 1-year high
- -59.9%
- Maximum drawdown, 3 years
- -86.7%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Nov 4, 2021 | Apr 8, 2025 | -93.6% | 858 days | Not yet recovered |
| Oct 8, 2021 | Oct 19, 2021 | -13.0% | 7 days | 7 days (Oct 28, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $135.6M
- EPS, diluted (TTM)
- -$1.41
- Revenue (TTM)
- $11.0M
- 52-week range
- $1.03 – $5.55
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $16.1M | $13.9M |
| Gross profit | $0 | $0 | $0 | $15.7M | $11.5M |
| Operating income | -$69.7M | -$123.5M | -$82.2M | -$89.5M | -$84.4M |
| Net income | -$76.0M | -$120.7M | -$73.8M | -$77.3M | -$79.6M |
| EPS (diluted) | -$2.53 | -$3.57 | -$1.85 | -$1.32 | -$1.28 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $2.8M | $0 | $11.0M | $0 | $0 |
| Net income | -$21.2M | -$35.6M | -$21.2M | -$18.4M | -$22.0M | -$18.1M | -$23.3M | -$25.3M |
| EPS (diluted) | -$0.35 | -$0.58 | -$0.35 | -$0.30 | -$0.35 | -$0.29 | -$0.37 | -$0.40 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$35.3M | -$89.3M | -$70.7M | -$57.7M | -$63.5M |
| Capital expenditure | -$540,000 | -$6.4M | -$6.7M | -$237,000 | -$9,000 |
| Free cash flow | -$35.9M | -$95.7M | -$77.4M | -$57.9M | -$63.5M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $152.3M | $0 | $6.1M | $59.0M | $742,000 |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $33.0M
- Total assets
- $54.9M
- Total liabilities
- $43.5M
- Total debt
- $17.8M
- Net debt
- -$1.0M
- Shareholders’ equity
- $11.4M
As of Jun 30, 2026 (filed Aug 13, 2026).
Short interest
- Shares sold short
- 4,678,522
- Days to cover
- 3.65
- Change vs previous report
- +17.9%
FINRA short interest, settlement date Sep 15, 2026.